 |
29 Products |  |
56 Diseases | | 29 Products |
|
157 Trials |  |
7438 News |  |
| «12...86878889909192939495969798» |
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia (clinicaltrials.gov) - Jul 8, 2012
P4, N=37, Completed, Sponsor: Michael Schiff, MD
Active, not recruiting --> Completed
- || Cervidil (dinoprostone) / Ferring
New P3 trial: Prostin and Propess in Induction of Labor (clinicaltrials.gov) - Jul 5, 2012
P3, N=200, Completed, Sponsor: Ain Shams University
- | Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC) (clinicaltrials.gov) - Jun 26, 2012
P2, N=40, Not yet recruiting, Sponsor: British Columbia Cancer Agency
- Menopur (menotropin) / Ferring
Clinical data: Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP (clinicaltrials.gov) - Jun 18, 2012
P=N/A, N=40, Completed, Sponsor: Centro Riproduzione e Andrologia
- Cervidil (dinoprostone) / Ferring
New P4 trial: Intravaginal Misoprostol Versus Dinoprostone Before Diagnostik Hysteroscopy (clinicaltrials.gov) - Jun 13, 2012
P4, N=30, Recruiting, Sponsor: Zekai Tahir Burak Maternity and Teaching Hospital
- Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
Enrollment closed: 1B Intravesical Administration of SCH 721015 (Ad-IFNa) in Admixture With SCH 209702 (Syn3) for The Treatment of BCG Refractory Superficial Bladder Cancer (clinicaltrials.gov) - Jun 13, 2012
P1b, N=9, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Biomarker, Enrollment open: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 11, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: PRECiSE 4: A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (clinicaltrials.gov) - May 29, 2012
P3, N=310, Completed, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease (clinicaltrials.gov) - May 24, 2012
P3, N=0, Withdrawn, Sponsor: UCB, Inc.
Active, not recruiting --> Completed N=35 --> 0
- Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas (clinicaltrials.gov) - May 24, 2012
P3, N=0, Withdrawn, Sponsor: UCB, Inc.
N=35 --> 0 N=200 --> 0
- Firmagon (degarelix) / Astellas, Ferring
Trial initiation date: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy (clinicaltrials.gov) - May 22, 2012
P2, N=50, Recruiting, Sponsor: British Columbia Cancer Agency
N=200 --> 0 Initiation date: Nov 2011 --> Apr 2012
- Firmagon (degarelix) / Astellas, Ferring
Enrollment open: Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy (clinicaltrials.gov) - May 22, 2012
P2, N=50, Recruiting, Sponsor: British Columbia Cancer Agency
Initiation date: Nov 2011 --> Apr 2012 Not yet recruiting --> Recruiting
- | Biomarker, New P4 trial: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - May 16, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: SCINTRA: Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNF? in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis (clinicaltrials.gov) - May 1, 2012
P3, N=20, Recruiting, Sponsor: University Hospital, Ghent
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment (clinicaltrials.gov) - Apr 18, 2012
P4, N=20, Recruiting, Sponsor: Baylor College of Medicine
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) (clinicaltrials.gov) - Apr 11, 2012
P=N/A, N=500, Recruiting, Sponsor: UCB, Inc.
- ||||||| Rekovelle (follitropin delta) / Ferring, Menopur (menotropin) / Ferring
Trial completion: MEGASET: MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer (clinicaltrials.gov) - Mar 21, 2012
P3, N=749, Completed, Sponsor: Ferring Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Euflexxa (hyaluronic acid) / Ferring
New P4 trial: Prediction of Response to Intra-articular Injections of Hyaluronic Acid for Knee Osteoarthritis (clinicaltrials.gov) - Mar 18, 2012
P4, N=207, Completed, Sponsor: American Orthopaedic Society for Sports Medicine
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: DoseFlex: Dosing Flexibility Study in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 15, 2012
P4, N=333, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed N=617 --> 333
- Pentasa (mesalamine) / Ferring, Takeda
Enrollment change: The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease" (clinicaltrials.gov) - Mar 8, 2012
P3, N=3, Terminated, Sponsor: Ferring Pharmaceuticals
N=617 --> 333 N=10 --> 3
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Mar 7, 2012
P3, N=156, Recruiting, Sponsor: UCB BIOSCIENCES GmbH
- Firmagon (degarelix) / Astellas, Ferring
New P2 trial, Metastases: A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer (clinicaltrials.gov) - Mar 5, 2012
P2, N=5, Terminated, Sponsor: Ottawa Hospital Research Institute
- Cetrotide (cetrorelix) / EMD Serono, Lutrelef (gonadorelin acetate) / Ferring
Enrollment closed: Reproductive Hormonal Alterations in Obesity (clinicaltrials.gov) - Mar 4, 2012
P=N/A, N=60, Active, not recruiting, Sponsor: University of Colorado, Denver
N=10 --> 3 Recruiting --> Active, not recruiting
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change: REALISTIC: Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Mar 1, 2012
P3, N=1648, Completed, Sponsor: UCB, Inc.
Recruiting --> Active, not recruiting N=1063 --> 1648
- Firmagon (degarelix) / Astellas, Ferring
PARP Biomarker: Androgen Deprivation Therapy Prior to Prostatectomy for Patients with Intermediate and High Risk Prostate Cancer (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=45, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- New P3 trial: Epidermal growth factor enemas versus mesalazine enemas for the treatment of mild-to-moderate active left-sided ulcerative colitis or proctitis (EUDRACT) - Feb 14, 2012
P3, N=50, Ongoing, Sponsor: University Hospitals of Leicester NHS Trust
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 12, 2012
P3, N=567, Completed, Sponsor: UCB, Inc.
N=1063 --> 1648 Active, not recruiting --> Completed
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: RAPID 2: A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 7, 2012
P3, N=857, Completed, Sponsor: UCB, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Menopur (menotropin) / Ferring, Bravelle (urofollitropin) / Ferring
Trial completion: Menopur Mixed Protocol (clinicaltrials.gov) - Feb 5, 2012
P4, N=122, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Completed
- ||| Zomacton (somatropin) / Ferring
Trial completion, Compliance: Evaluation of Overall Compliance and Duration of Zomacton (clinicaltrials.gov) - Feb 5, 2012
P=N/A, N=87, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy (clinicaltrials.gov) - Feb 1, 2012
P3, N=386, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 29, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB, Inc.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Jan 25, 2012
P3, N=880, Active, not recruiting, Sponsor: UCB Pharma SA
- | Firmagon (degarelix) / Astellas, Ferring
New P4 trial: FIT: Firmagon (Degarelix) Intermittent Therapy (clinicaltrials.gov) - Jan 17, 2012
P4, N=144, Recruiting, Sponsor: Canadian Urology Research Consortium
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: A Long Term Safety Study of Degarelix in Patients With Prostate Cancer (clinicaltrials.gov) - Jan 9, 2012
P3, N=77, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Cervidil (dinoprostone) / Ferring
Enrollment change: Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM) (clinicaltrials.gov) - Jan 4, 2012
P4, N=70, Completed, Sponsor: Liverpool Women's NHS Foundation Trust
Active, not recruiting --> Completed N=100 --> 70
- Cervidil (dinoprostone) / Ferring
Trial completion: Feasibility and Acceptability of the Combination of Propess and AN24 Monica for Outpatient Labour Induction (PRAM) (clinicaltrials.gov) - Jan 4, 2012
P4, N=70, Completed, Sponsor: Liverpool Women's NHS Foundation Trust
N=100 --> 70 Recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA
- | Firmagon (degarelix) / Astellas, Ferring
Trial termination: A Degarelix Trial in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 19, 2011
P3, N=288, Terminated, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data.
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial initiation date, Combination therapy: SPEED: Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 14, 2011
P4, N=120, Active, not recruiting, Sponsor: UCB, Inc.
Active, not recruiting --> Terminated; Inadequate recruitment resulting in a too low patient number for collection of long term efficacy data. Initiation date: Sep 2011 --> Dec 2011
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=100, Active, not recruiting, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Initiation date: Sep 2011 --> Dec 2011 Recruiting --> Active, not recruiting
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 13, 2011
P3, N=127, Completed, Sponsor: Korea Otsuka Pharmaceutical Co.,Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Dec 12, 2011
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
- ||||| Firmagon (degarelix) / Astellas, Ferring
New P2 trial: Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer (clinicaltrials.gov) - Dec 12, 2011
P2, N=76, Completed, Sponsor: Ferring Pharmaceuticals
- Cervidil (dinoprostone) / Ferring
Trial completion: Double Balloon Catheter Versus Dinoprostone Vaginal Insert for Cervical Ripening. (clinicaltrials.gov) - Dec 11, 2011
P4, N=210, Completed, Sponsor: Universit
Active, not recruiting --> Completed Recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer (clinicaltrials.gov) - Dec 7, 2011
P3, N=246, Completed, Sponsor: Ferring Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Firmagon (degarelix) / Astellas, Ferring
Trial completion: Efficacy and Safety of Degarelix One Month Dosing Regimen in Korean Patients With Prostate Cancer (clinicaltrials.gov) - Dec 6, 2011
P3, N=157, Completed, Sponsor: Ferring Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | FSH-GEX (follicle stimulating hormone) / Glycotope
Trial completion: Single Dose FSH-GEX (clinicaltrials.gov) - Nov 24, 2011
P1, N=18, Completed, Sponsor: Glycotope GmbH
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| FSH-GEX (follicle stimulating hormone) / Glycotope
New P1 trial: Multiple Dose FSH-GEX(TM) in Healthy Volunteers (clinicaltrials.gov) - Nov 20, 2011
P1, N=57, Completed, Sponsor: Glycotope GmbH
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Nov 17, 2011
P3, N=3, Terminated, Sponsor: UCB, Inc.
Suspended --> Terminated; Termination of study due to low enrollment. There were no safety issues.